About Trafficking protein particle complex subunit 13
Trafficking protein particle complex subunit 13 (TRAPPC13) is a protein
from Homo sapiens identified by UniProt accession
A5PLN9, 417 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | Trafficking protein particle complex subunit 13 |
| UniProt accession | A5PLN9 |
| Gene | TRAPPC13 |
| Organism | Homo sapiens |
| Length | 417 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (21)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.51
- reticulocyte count · score 0.20
- neuroimaging measurement · score 0.10
- brain volume measurement · score 0.10
- reticulocyte measurement · score 0.09
- brain measurement · score 0.09
- body height · score 0.09
- thalamus volume · score 0.08
- refractive error measurement · score 0.07
- feeling tense measurement · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A5PLN9-F1 | alphafold | PREDICTED | 86.72 | — |
Amino-acid sequence (417 residues)
MEVNPPKQEH LLALKVMRLT KPTLFTNIPV TCEEKDLPGD LFNQLMRDDP STVNGAEVLM LGEMLTLPQN FGNIFLGETF SSYISVHNDS NQVVKDILVK ADLQTSSQRL NLSASNAAVA ELKPDCCIDD VIHHEVKEIG THILVCAVSY TTQAGEKMYF RKFFKFQVLK PLDVKTKFYN AESDLSSVTD EVFLEAQIQN MTTSPMFMEK VSLEPSIMYN VTELNSVSQA GECVSTFGSR AYLQPMDTRQ YLYCLKPKNE FAEKAGIIKG VTVIGKLDIV WKTNLGERGR LQTSQLQRMA PGYGDVRLSL EAIPDTVNLE EPFHITCKIT NCSERTMDLV LEMCNTNSIH WCGISGRQLG KLHPSSSLCL ALTLLSSVQG LQSISGLRLT DTFLKRTYEY DDIAQVCVVS SAIKVES
Explore Trafficking protein particle complex subunit 13 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets